HZN-825 for Idiopathic Pulmonary Fibrosis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests HZN-825, a new oral medicine, in people with Idiopathic Pulmonary Fibrosis (IPF). The goal is to see if it can help by blocking a receptor that causes lung scarring. The study will check its safety and effectiveness over several months.
Who Is on the Research Team?
MD
Principal Investigator
Amgen
Are You a Good Fit for This Trial?
Adults aged 18-80 with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) for at least 1 year but not more than 7 years, who have an FEV1/FVC ratio ≥0.7 and HRCT showing significant fibrosis are eligible. They must be able to follow the trial protocol without planned changes in IPF therapy, not have severe other diseases or conditions, and agree to use effective birth control.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive HZN-825 or placebo for 52 weeks in a double-blind manner
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extension
Participants may opt into a 52-week open-label extension to continue receiving HZN-825
What Are the Treatments Tested in This Trial?
Interventions
- HZN-825
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amgen
Lead Sponsor
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London
Horizon Therapeutics Ireland DAC
Lead Sponsor